US Patent 11292842 Anti-PD-1 antibodies for treatment of lung cancer
Patent 11292842 was granted and assigned to Regeneron Pharmaceuticals on April, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 14 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
112928420
Date of Patent
April 5, 2022
0Patent Application Number
164866880
Date Filed
February 20, 2018
0Official Website
Patent Primary Examiner
CPC Code
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
112928420
Date of Patent
April 5, 2022
0Patent Application Number
164866880
Date Filed
February 20, 2018
0Official Website
Patent Primary Examiner
CPC Code
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Apr, 2022
Golden AI
Edits made to:
Infobox (+13 properties)
Article (+372 characters)
US Patent 11292842 Anti-PD-1 antibodies for treatment of lung cancer
Article
The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11292842
Date of patent
April 5, 2022
Patent application number
16486688
Date Filed
February 20, 2018
Patent primary examiner
Find more entities like US Patent 11292842 Anti-PD-1 antibodies for treatment of lung cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
